- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Biogen Idec Inc. (BIIB)
by latest | most commented
-
P/E - Value Plays or Value Traps?
-
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
-
Dealmaking Sweeps the Biotech Sector
-
Is IBB the Best Biotech ETF?
-
Spectrum Pharmaceuticals: Optimistic About Zevalin's Prospects
-
Amylin, Biogen Idec Stand to Benefit from Icahn Board Victories
-
S&P 500: Ten Stocks to Watch
-
Shumway Beefs Up Teva, Cisco Positions
-
Nine Value Companies to Watch
-
Hedge Fund Performance Update for May and YTD
-
Options Trader Friday Update: AXL, PALM, POT, XLF, EMR, AA, BIIB
-
Wall Street Breakfast: Must-Know News
-
Preview from Europe: U.S. Jobs Data Due; Brown Reshuffles the Deck
-
Biogen and Icahn: Call It a Draw and Get Back to Business
-
Shareholder Activists Week in Review: Winners and Losers
-
Preview from Europe: The Great Bond Massacre Spills Over onto Stocks
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
What's in Store for Amylin and Biogen Idec's Shareholder Meetings?
-
FDA, Clinical Trial Updates: Biogen, Roche, Salix, Cell Therapeutics, Pfizer
-
Michael Mauer Leaves Citi for Icahn
-
Goldman Sachs Busy Editing Conviction Buy and Sell Lists
-
Apple and the QQQ ETF: High-Beta, Growth-Oriented, Tech-Driven Exposure
-
Preview from Europe: Geithner's Soothing Words Send Stocks Higher
-
Preview from Europe: Stocks Facing Green Shoots, Or Just Weeds?
-
New MS Therapies: A Hard Pill to Swallow?
-
Closing Update: Streak Stretches Six
-
Wall Street Breakfast: Must-Know News
-
Preview from Europe: Another Late Rally Lifts Markets
-
Key Upcoming Earnings Reports
-
Wall Street Breakfast: Must-Know News
-
Why Is Biogen Idec on the Rise?
-
Thursday Options Update: FRX, CSX, RIMM & BIIB
-
Shumway Capital: Visa Is Top Holding
-
Biogen to Collaborate on Cancer Treatment
-
Biotech M&A Action: We've Only Just Begun
-
Where Might Genentech Investors Redeploy $47B?
-
Big Mergers Could Mean Sweet Gains for Biotech
-
Maverick Capital's 13F Filing for Q408
-
Carl Icahn's Top Three Stock Ideas
-
Biotech Going Generic Like Big Pharma?
-
After Thursday's Bloodbath, Is Biopharma a Buy?